Clinical Trials /

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

NCT02595905

Description:

This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast cancer that has come back (recurrent) or has or has not spread to the brain (brain metastases). Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. It is not yet known if cisplatin is more effective with or without veliparib in treating patients with triple-negative and/or BRCA mutation-associated breast cancer.

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Active, not recruiting

Phase:

Phase 2

URL:

https://clinicaltrials.gov/show/NCT02595905

Trial Eligibility

Document

Title

  • Brief Title: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
  • Official Title: Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

Clinical Trial IDs

  • ORG STUDY ID: NCI-2015-01912
  • SECONDARY ID: NCI-2015-01912
  • SECONDARY ID: S1416
  • SECONDARY ID: S1416
  • SECONDARY ID: S1416
  • SECONDARY ID: U10CA180888
  • NCT ID: NCT02595905

Conditions

  • Metastatic BRCA-Associated Breast Carcinoma
  • Metastatic Breast Carcinoma
  • Metastatic Malignant Neoplasm in the Brain
  • Metastatic Triple-Negative Breast Carcinoma
  • Recurrent Breast Carcinoma
  • Stage IV Breast Cancer AJCC v6 and v7

Interventions

DrugSynonymsArms
CisplatinAbiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, PlatosinArm I (cisplatin and placebo)
VeliparibABT-888, PARP-1 inhibitor ABT-888Arm II (cisplatin and veliparib)

Purpose

This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast cancer that has come back (recurrent) or has or has not spread to the brain (brain metastases). Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. It is not yet known if cisplatin is more effective with or without veliparib in treating patients with triple-negative and/or BRCA mutation-associated breast cancer.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To compare the efficacy of cisplatin with or without ABT-888 (veliparib) on
      progression-free survival (PFS) in each of the following groups: patients with germline BRCA
      (gBRCA) mutation-associated breast cancer, patients with germline BRCA wild-type breast
      cancer who have evidence of BRCAness phenotype, and patients with germline BRCA wild-type
      breast cancer who do not have evidence of BRCAness phenotype.

      II. To compare the efficacy of cisplatin with or without ABT-888 on PFS in patients with
      triple negative and/or gBRCA mutation-associated breast cancer and brain metastases. (Brain
      Metastases Cohort)

      SECONDARY OBJECTIVES:

      I. For patients with gBRCA mutation associated breast cancer (group "i" above) or
      triple-negative breast cancer (TNBC) with (group "ii") or without (group "iii") BRCAness
      phenotype, to compare the efficacy of cisplatin with or without ABT-888 on overall survival
      (OS), response rate, and clinical benefit rate.

      II. To compare the differential benefit of ABT-888 across the three groups using both PFS and
      OS as outcomes.

      III. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with
      or without ABT-888 on OS.

      IV. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with or
      without ABT-888 on intracranial and extracranial response rates (intracranial by Response
      Assessment Neuro-Oncology Criteria [RANO] and extracranial by Response Evaluation Criteria in
      Solid Tumors version 1.1 [RECIST 1.1]).

      V. To compare toxicities of ABT-888 to placebo in each of the four groups separately.

      TRANSLATIONAL OBJECTIVES:

      I. To evaluate the impact of homologous recombination deficiency score (independent of other
      BRCAness markers) on response rate (RR) and PFS in patients treated with chemotherapy versus
      chemotherapy plus ABT-888.

      II. To evaluate the overlap among various markers utilized to define the BRCAness phenotype.

      III. To evaluate the combined impact of PAM50 basal subtype and BRCAness phenotype on RR and
      PFS in patients treated with chemotherapy versus chemotherapy plus ABT-888.

      IV. To evaluate the impact of BRCA1 mRNA expression (independent other BRCAness markers) on
      response rate (RR) and PFS in patients treated with chemotherapy versus chemotherapy plus
      ABT-888.

      V. Application of somatic BRCAness phenotype markers on metastatic tumor tissue to identify
      patients likely to benefit from platinum-based therapy and ABT-888.

      VI. To determine the overlap of BRCA phenotype (germline BRCA, BRCA-like, non-BRCA-like) with
      tissue PD-L1 status and to determine if ABT-888 (veliparib) benefit in BRCA-like patients is
      maintained when adjusting for PD-L1 status.

      VII. To evaluate circulating tumor cells - homologous recombination deficiency (CTC-HRD)
      status as a predictive biomarker of response to treatment with cisplatin plus ABT-888
      (veliparib) versus cisplatin plus placebo.

      VIII. To evaluate circulating tumor deoxyribonucleic acid (ctDNA) HRR (homologous
      recombination repair) mutation status as a predictive marker of response to treatment with
      cisplatin plus ABT-888 (veliparib) versus cisplatin plus placebo.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive cisplatin intravenously (IV) over 1 hour on day 1 and placebo orally
      (PO) twice daily (BID) on days 1-14. Cycles repeat every 21 days in the absence of disease
      progression or unacceptable toxicity.

      ARM II: Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14.
      Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 9 weeks for 54 weeks,
      every 18 weeks until progression, and then every 6 months for up to 5 years after
      registration.

Trial Arms

NameTypeDescriptionInterventions
Arm I (cisplatin and placebo)Active ComparatorPatients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
  • Cisplatin
Arm II (cisplatin and veliparib)ExperimentalPatients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
  • Cisplatin
  • Veliparib

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have metastatic and/or recurrent (distant or locoregionally recurrent)
             breast cancer and be HER2 non-over expressing per 2013 American Society of Clinical
             Oncology (ASCO)-College of American Pathologists (CAP) HER testing guidelines (0 or 1+
             by immunohistochemistry [IHC]; and/or HER2 ratio < 2.0 and HER2 copy number < 4
             signals/cell by in-situ hybridization [ISH])

               -  Local Regional Recurrence

                    -  In the breast (after preserving therapy)

                    -  In the chest wall (after mastectomy)

                    -  In the ipsilateral/parasternal/infra-or supraclavicular lymph nodes

                    -  In the skin of the chest wall (not breast)

                    -  In the reconstructed breast

          -  Patients must also meet at least one of the following criteria:

               -  Triple negative: histologically confirmed primary and/or metastatic site that is
                  estrogen receptor (ER)-negative (=< 1%), progesterone receptor (PR)-negative (=<
                  1%), and HER2-negative

               -  BRCA mutation: previously confirmed deleterious breast cancer 1, early onset
                  (BRCA1) or breast cancer 2, early onset (BRCA2) germline mutation or suspected
                  deleterious BRCA1 or BRCA2 germline mutation if the classification being used is
                  the 5-tier classification; documentation of germline test results are required

          -  Patients must have measurable or non-measurable disease; patients must have a
             chest/abdominal/pelvis computed tomography (CT) scan (or positron emission tomography
             [PET]/CT of diagnostic quality, conventional or spiral) prior to registration; if the
             patient is unable to undergo CT with IV contrast due to allergy or renal
             insufficiency, a non-contrast CT may be performed; all scans needed for assessment of
             measurable disease must be performed within 28 days prior to registration;
             non-measurable disease must be assessed within 42 days prior to registration; all
             disease must be assessed and documented on the Baseline Tumor Assessment Form

          -  Patients must have adequate tissue available and must agree to have specimens
             submitted for germline BRCA deoxyribonucleic acid (DNA) sequencing and other
             correlative studies

               -  NOTE: Blood for BRCA mutation testing is to be collected and submitted after
                  registration but before treatment

          -  Patients must have had =< 1 prior cytotoxic regimen for metastatic disease (unless
             enrolling in the Progressive Brain Metastases Cohort); note that endocrine and
             immunotherapies do not count as cytotoxic regimens

          -  Patients must have completed any prior radiation therapy and hormonal therapy at least
             14 days prior to registration

          -  Patients may receive bisphosphonates or denosumab concurrently with study treatment;
             if started prior to registration, it must be started at least 7 days prior to
             registration

          -  Patients must have recovered to =< grade 2 following a significant adverse event or
             toxicity attributed to previous anti-cancer treatment except neurotoxicity which must
             be =< grade 1

          -  Patients must have a performance status of 0-2 by Zubrod criteria

          -  Absolute neutrophil count (ANC) of >= 1,500/mL (within 21 days prior to registration);
             patients must not have had a blood transfusion within 28 days prior to registration

          -  Hemoglobin >= 10 g/dL (within 21 days prior to registration); patients must not have
             had a blood transfusion within 28 days prior to registration

          -  Platelet count >= 100,000/ mL (within 21 days prior to registration); patients must
             not have had a blood transfusion within 28 days prior to registration

          -  Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome or if liver
             metastases are present) (within 21 days prior to registration)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x
             institutional upper limit of normal (IULN) (or =< 5 x IULN if liver metastases are
             present) (within 21 days prior to registration)

          -  Patients must have adequate renal function with serum creatinine level =< IULN within
             21 days prior to registration

          -  Patients must have serum chemistries (including potassium and magnesium) within 21
             days prior to registration to obtain baseline values

          -  Patients must be able to swallow whole capsules

          -  Patients with a history of uncontrolled seizure disorder; including focal or
             generalized seizure may not have had a seizure within one year prior to registration

          -  Patients with known brain metastases must either meet the additional criteria and
             enroll as part of the Progressive Brain Metastases Cohort, or have clinically
             controlled neurologic symptoms, defined as surgical excision and/or radiation therapy
             followed by 14 days of stable neurologic function prior to registration; patients with
             previously incidentally discovered or asymptomatic brain metastasis(es) must receive
             surgical excision and/or radiation therapy prior to registration; patients with
             progressive brain metastases following prior treatment are not eligible for the
             Standard Cohort, but may be considered for the Progressive Brain Metastases Cohort

          -  Patients must have a complete history and physical examination within 28 days prior to
             registration

          -  Patients of childbearing potential must not be pregnant (negative pregnancy test) or
             nursing due to the possibility of harm to a fetus or nursing infant from this
             treatment regimen; men and women of reproductive potential must have agreed to use an
             effective contraceptive method for 6 months after completion of study treatment; a
             woman is considered to be of "reproductive potential" if she has had menses at any
             time in the preceding 12 consecutive months; in addition to routine contraceptive
             methods, "effective contraception" also includes heterosexual celibacy and surgery
             intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined
             as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at
             any point a previously celibate patient chooses to become heterosexually active during
             the time period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for five years

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines

          -  As part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study had been
             entered in the system

          -  Progressive Brain Metastases Cohort

               -  S1416 is one study with two cohorts; patients who have progressive brain
                  metastases after surgical excision and/or intracranial radiation will be in the
                  Progressive Brain Metastases Cohort and will require a baseline magnetic
                  resonance imaging (MRI); patients with previously treated brain metastases,
                  stable disease and stable neurologic function for 14 days prior to trial
                  registration will be in the Standard Cohort and may obtain MRI of the brain at
                  the physician's discretion; randomization and treatment is the same for both
                  cohorts

               -  In addition to all of the previous eligibility criteria, patients with
                  progressive brain metastases who do not satisfy the conditions to enroll in the
                  standard cohort (neurologic stability for 14 days following surgery and/or
                  radiation therapy) must also meet the following criteria to enroll as part of the
                  brain metastases cohort:

                    -  Patients with progressive brain metastases must have a baseline brain MRI
                       within 28 days prior to registration; brain metastases must be progressive
                       and >= 10 mm in longest dimension on radiographic imaging AFTER prior
                       intracranial radiation (IR) therapy (i.e., whole brain radiation therapy
                       [WBRT], stereotactic radiosurgery [SRS], gamma knife [GK] or local
                       equivalent); patients must not have evidence of diffuse leptomeningeal
                       disease on brain MRI or by previously documented cerebrospinal fluid (CSF)
                       cytology; discrete dural metastases are permitted; there must be no evidence
                       of hemorrhage or impending herniation on baseline brain imaging; patients
                       with contraindication to gadolinium-enhanced MRI imaging are not eligible

                    -  Patients must be on a stable or decreasing dose of steroids for >= 7 days
                       prior to registration

                    -  If patient had an open brain biopsy, at least 28 days must have elapsed
                       between biopsy and registration

                    -  Patients enrolling in the Progressive Brain Metastases Cohort can have
                       received up to 3 prior lines of cytotoxic chemotherapy for metastatic
                       disease; note that for enrollment in the standard cohort, patients must have
                       had =< 1 prior cytotoxic regimen for metastatic disease

        Exclusion Criteria:

          -  Patients must not have received prior cisplatin or poly (adenosine diphosphate
             [ADP]-ribose) polymerase (PARP) inhibitors; prior carboplatin in the
             adjuvant/neoadjuvant setting is allowed, if completed more than 12 months prior to
             study entry

          -  Patients must not have received any chemotherapy within 14 days prior to registration

          -  Patients must not have received any immunotherapy, biologic or any investigational
             drug within 28 days prior to registration; patients must not have received bevacizumab
             within 42 days prior to registration

          -  Patients must not have a clinically relevant hearing impairment >= grade 2

          -  Patients must not have treatment-related acute myeloid leukemia (AML)
             (t-AML)/myelodysplastic syndrome (MDS) or features suggestive of AML/MDS

          -  Patients must not have had prior allogeneic bone marrow transplant or double umbilical
             cord blood transplantation

          -  Patients must not have any incidence of or uncontrolled medical illness (e.g. active
             cardiac symptoms, active systemic infection, etc.) that would limit the patient's
             ability to participate in the protocol

          -  Patients must not have baseline peripheral neuropathy that exceeds grade 1
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression-free survival (PFS)
Time Frame:Time from registration (randomization) to progression or death due to any cause, assessed up to 5 years
Safety Issue:
Description:Veliparib will be compared to no veliparib in the BRCA mutation-carriers, BRCA mutation-negative BRCAness-like group, and BRCA mutation-negative non-BRCA-like group. A stratified log-rank test will be used to compare PFS between the two arms in an intention to treat (ITT) analysis where stratification is by line of therapy. In the Progressive Brain Metastases Cohort, veliparib will be compared to no veliparib in patients with active brain metastases that are progressive after prior intracranial therapy. A stratified log-rank test will be used to compare PFS between the two arms in an ITT analysis where stratification is by Modified Breast-Graded Prognostic Assessment (GPA) and prior systemic therapies.

Secondary Outcome Measures

Measure:Overall survival (OS)
Time Frame:Time from registration to death due to any cause, assessed up to a minimum of 5 years
Safety Issue:
Description:Veliparib will be compared to no veliparib in the BRCA mutation-carriers, BRCA mutation-negative BRCAness-like group, and BRCA mutation-negative non-BRCA-like group. A stratified log-rank test will be used to compare OS between the two arms in an ITT analysis where stratification is line by line. In the Progressive Brain Metastases Cohort, veliparib will be compared to no veliparib in patients with active brain metastases that are progressive after prior intracranial therapy. A stratified log-rank test will be used to compare OS between the two arms in an ITT analysis where stratification is by Modified Breast-GPA and prior systemic therapies.
Measure:Response rate (measurable disease only)
Time Frame:Up to 5 years
Safety Issue:
Description:Response rate will be analyzed for patients with measurable disease. Patients who achieve complete or partial response will be classified as having a response. The primary analyses will be conducted using these binary responses using Fisher's exact test and logistic regression.
Measure:Clinical benefit rate
Time Frame:Up to 5 years
Safety Issue:
Description:Clinical benefit will be assessed in all patients and will include those with complete or partial response and those with stable disease for 6 months. The primary analyses will be conducted using these binary responses using Fisher's exact test and logistic regression.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:National Cancer Institute (NCI)

Last Updated

August 19, 2021